Polaryx names Will Charlton CMO, 2026 trial set
Polaryx Therapeutics, Inc. (PLYX) reported the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026.
Rhea-AI Filing Summary
Polaryx Therapeutics, Inc. (PLYX) reported the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of rare disease and pediatric drug development experience, including senior roles at Tyra Biosciences, Spruce Biosciences, 89bio, Ascendis Pharma, and Allergan.
The company highlighted his role in leading Phase 2 rare disease programs and redesigning clinical strategies for pediatric indications. Polaryx reiterated plans to initiate SOTERIA, a Phase 2 open-label, single-arm trial of PLX-200 in multiple lysosomal storage disorders, in the fourth quarter of 2026, initially at sites in the United States and then other jurisdictions.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Effective date of Chief Medical Officer appointment: September 1, 2026
Safe to proceed letter date: October 2025
Planned SOTERIA trial initiation timing: Q4 2026
+3 more
6 metrics
Effective date of Chief Medical Officer appointment
September 1, 2026
Date Dr. Will Charlton’s role as CMO at Polaryx becomes effective
Safe to proceed letter date
October 2025
Month and year when the FDA provided a safe to proceed letter for SOTERIA
Planned SOTERIA trial initiation timing
Q4 2026
Targeted start period for the Phase 2 SOTERIA trial of PLX-200
SOTERIA trial phase
Phase 2
Development stage of the SOTERIA basket trial for PLX-200
Lysosomal storage disorders in SOTERIA
4
Number of LSDs targeted in the SOTERIA trial: CLN2, CLN3, Krabbe disease, Sandhoff disease
Estimated share of LSD population
approximately one quarter
Proportion of lysosomal storage disorder population represented by SOTERIA’s target indications
Key Terms
lysosomal storage disorders, Phase 2, open-label, single-arm trial, +2 more
6 terms
lysosomal storage disorders medical
"rare pediatric lysosomal storage disorders (“LSDs”), today announced the appointment"
A group of inherited conditions where cells cannot break down and clear certain molecules, like a clogged recycling center inside cells causing harmful buildup that damages organs and the nervous system. Investors care because these disorders create clear targets for specialized treatments, often qualify for orphan-drug incentives and accelerated review, and can drive focused clinical programs and high-value niche markets if therapies prove safe and effective.
Phase 2 medical
"Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation"
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
open-label medical
"SOTERIA is a Phase 2, open-label, single-arm trial intended to assess the safety"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
single-arm trial medical
"SOTERIA is a Phase 2, open-label, single-arm trial intended to assess the safety"
natural history study medical
"A natural history study is a preplanned observational study intended to track the course"
A natural history study is an observational research project that follows people with a specific disease over time to document how the condition develops, what symptoms appear, and typical outcomes without testing a new treatment. Investors care because these studies create a factual map of the disease—like a road atlas for drug developers—helping companies design efficient clinical trials, choose meaningful goals for approval, estimate how many patients could benefit, and reduce the guesswork and risk around a drug’s path to market.
expedited approval pathway regulatory
"Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway"
An expedited approval pathway is a regulatory process that lets a drug, medical device or treatment reach the market faster than the standard route when it addresses a serious condition or unmet medical need. For investors, it matters because faster reviews can shorten time to sales and reduce development costs—like a fast lane at an airport—while still carrying regulatory and clinical risks if safety or effectiveness questions remain.
FAQ
What executive change did PLYX announce on September 1, 2026?
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as its Chief Medical Officer, effective September 1, 2026. He brings extensive experience in rare diseases and pediatric drug development, including prior CMO and senior clinical development roles at several biotechnology companies.
What is Dr. Will Charlton’s background relevant to PLYX?
Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of rare disease and pediatric drug development experience. He previously held senior roles at Tyra Biosciences, Spruce Biosciences, and 89bio, where he led Phase 2 programs and pediatric-focused clinical strategies.
What is the SOTERIA trial mentioned by PLYX?
The SOTERIA trial is a planned Phase 2, open-label, single-arm study of PLX-200 in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease. It is intended to assess safety, tolerability, and clinical activity and to inform PLX-200’s future development.
When does PLYX plan to initiate the SOTERIA Phase 2 trial?
Polaryx plans to initiate the SOTERIA Phase 2 trial in the fourth quarter of 2026, starting with trial sites in the United States and then expanding to other foreign jurisdictions, following a safe to proceed letter from the FDA received in October 2025.
Which diseases will PLX-200 target in the SOTERIA trial for PLYX?
In SOTERIA, PLX-200 will be evaluated in CLN2, CLN3, Krabbe disease, and Sandhoff disease, all lysosomal storage disorders. Polaryx believes these patient populations collectively represent approximately one quarter of the overall lysosomal storage disorder population.
How will SOTERIA incorporate control comparisons for PLYX?
Although SOTERIA is an open-label trial, the CLN2 and CLN3 cohorts will include analyses comparing natural history data as a control arm to the PLX-200 treated arm, using preplanned observational data on disease course for comparison.
AI-generated analysis. How Rhea-AI works. Not financial advice.
